2025年4月11日，歐盟食品安全局（EFSA）發布消息，歐盟食品安全局發布關于沉積型斜發沸石（clinoptilolite of sedimentary origin）作為所有動物飼料添加劑的授權更新申請的評估。
經過評估，專家小組得出結論，該添加劑在授權使用條件下對目標物種、消費者和環境都是安全的。在授權更新的情況下，無需評估添加劑的功效。部分原文報道如下：
Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the assessment of the application for renewal of authorisation of clinoptilolite of sedimentary origin as a technological feed additive (binder and anticaking agents) for all animal species. The applicant provided evidence that the additive currently on the market complies with the existing conditions of authorisation. The Panel concludes that clinoptilolite of sedimentary origin remains safe for all animal species, consumers and the environment under the authorised conditions of use. Regarding user safety, the additive is not a skin nor an eye irritant but should be considered a skin and respiratory sensitiser. Inhalation and dermal exposure are considered a risk. There is no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.
經過評估，專家小組得出結論，該添加劑在授權使用條件下對目標物種、消費者和環境都是安全的。在授權更新的情況下，無需評估添加劑的功效。部分原文報道如下：
Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the assessment of the application for renewal of authorisation of clinoptilolite of sedimentary origin as a technological feed additive (binder and anticaking agents) for all animal species. The applicant provided evidence that the additive currently on the market complies with the existing conditions of authorisation. The Panel concludes that clinoptilolite of sedimentary origin remains safe for all animal species, consumers and the environment under the authorised conditions of use. Regarding user safety, the additive is not a skin nor an eye irritant but should be considered a skin and respiratory sensitiser. Inhalation and dermal exposure are considered a risk. There is no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.
